Lyell Immunopharma, Inc. <LYEL.O>: Stifel initiates coverage with buy rating; target price $36
LYEL•Related News
Zscaler schedules fiscal Q4 2026 earnings call
ZS•
Sempra Q2 FY26 GAAP earnings rise 72.67% to $796 million
SRE•
Helix returns to profit in Q2 FY26 with net income of $22.7 million; revenue rises 21% to $304 million vs Q2 FY25
HLX•
Revolution Medicines, Inc. <RVMD.O>: Wedbush raises target price to $201 from $192.1
RVMD•
Ensysce Biosciences completes Cy Biopharma acquisition
ENSC•